Levofloxacin Versus Ceftriaxone and Azithromycin Combination in the Treatment of Community Acquired Pneumonia in Hospitalized Patients.

Q3 Medicine
Mehran Izadi, Banafsheh Dadsetan, Zeinab Najafi, Sirous Jafari, Elham Mazaheri, Omid Dadras, Hajar Heidari, SeyedAhmad SeyedAlinaghi, Fabricio Voltarelli
{"title":"Levofloxacin Versus Ceftriaxone and Azithromycin Combination in the Treatment of Community Acquired Pneumonia in Hospitalized Patients.","authors":"Mehran Izadi, Banafsheh Dadsetan, Zeinab Najafi, Sirous Jafari, Elham Mazaheri, Omid Dadras, Hajar Heidari, SeyedAhmad SeyedAlinaghi, Fabricio Voltarelli","doi":"10.2174/1574891X13666181024154526","DOIUrl":null,"url":null,"abstract":"BACKGROUND\nIn Asia, an estimated one million deaths are caused by communityacquired pneumonia (CAP) each year. Despite the high mortality in elderly people, a large number of CAP patients have been treated and survived with optimal life expectancy. A few studies have been done on adult CAP therapeutic approaches in Asia. Moreover, differences have been noted between these studies and European data. We aimed to investigate the efficacy of oral Levofloxacin (TAVANEX), 750 mg, once daily for five days versus parenteral Ceftriaxone 1gr BD, plus oral Azithromycin (250 mg, once daily) for seven to ten days (standard regimen) in CAP treatment.\n\n\nMATERIALS AND METHODS\nWe conducted a prospective randomized trial among 150 patients with CAP in Qaem Hospital of Alborz city from December 2016 to June 2017. A group of CAP patients were randomized in two treatment groups. One group was treated with oral Levofloxacin (TAVANEX), 750 mg, once daily for five days and the other group with parenteral Ceftriaxone 1gr BD plus oral Azithromycin (250 mg, once daily) for seven to ten days (standard regimen). The efficacy and side effects of the assigned drugs were compared between two groups. The probability level for statistical significance was set at P ≤ 0.05.\n\n\nRESULTS\nThe body temperature (P value=0.09), WBC count (P value=0.15), respiratory sounds (P value=0.18) and admission duration (P value=0.15) showed no significant differences after treatment between two groups. There was no report of hospital mortality, clinical deterioration and antibiotic escalation during hospital admission in both groups of study. In standard regimen group, only two (2.7%) patients had skin rash while in Levofloxacin group one case (1.3%) had skin rash, two patients (2.7%) had gastrointestinal problems and three (4%) patients showed central nervous system (CNS) complications. In both groups, the reticulonodular pattern was more frequently observed in Chest X-ray. Although standard regimen group (n=27, 36%) showed more consolidation than patients in Levofloxacin group (n=22, 29.3%), and the ground glass pattern was observed more in Levofloxacin group.\n\n\nCONCLUSION\nWe concluded that monotherapy with oral Levofloxacin was as effective as treatment with Ceftriaxone plus Azithromycin combination in patients with CAP who required hospitalization.","PeriodicalId":20909,"journal":{"name":"Recent patents on anti-infective drug discovery","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"12","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Recent patents on anti-infective drug discovery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1574891X13666181024154526","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 12

Abstract

BACKGROUND In Asia, an estimated one million deaths are caused by communityacquired pneumonia (CAP) each year. Despite the high mortality in elderly people, a large number of CAP patients have been treated and survived with optimal life expectancy. A few studies have been done on adult CAP therapeutic approaches in Asia. Moreover, differences have been noted between these studies and European data. We aimed to investigate the efficacy of oral Levofloxacin (TAVANEX), 750 mg, once daily for five days versus parenteral Ceftriaxone 1gr BD, plus oral Azithromycin (250 mg, once daily) for seven to ten days (standard regimen) in CAP treatment. MATERIALS AND METHODS We conducted a prospective randomized trial among 150 patients with CAP in Qaem Hospital of Alborz city from December 2016 to June 2017. A group of CAP patients were randomized in two treatment groups. One group was treated with oral Levofloxacin (TAVANEX), 750 mg, once daily for five days and the other group with parenteral Ceftriaxone 1gr BD plus oral Azithromycin (250 mg, once daily) for seven to ten days (standard regimen). The efficacy and side effects of the assigned drugs were compared between two groups. The probability level for statistical significance was set at P ≤ 0.05. RESULTS The body temperature (P value=0.09), WBC count (P value=0.15), respiratory sounds (P value=0.18) and admission duration (P value=0.15) showed no significant differences after treatment between two groups. There was no report of hospital mortality, clinical deterioration and antibiotic escalation during hospital admission in both groups of study. In standard regimen group, only two (2.7%) patients had skin rash while in Levofloxacin group one case (1.3%) had skin rash, two patients (2.7%) had gastrointestinal problems and three (4%) patients showed central nervous system (CNS) complications. In both groups, the reticulonodular pattern was more frequently observed in Chest X-ray. Although standard regimen group (n=27, 36%) showed more consolidation than patients in Levofloxacin group (n=22, 29.3%), and the ground glass pattern was observed more in Levofloxacin group. CONCLUSION We concluded that monotherapy with oral Levofloxacin was as effective as treatment with Ceftriaxone plus Azithromycin combination in patients with CAP who required hospitalization.
左氧氟沙星与头孢曲松、阿奇霉素联合治疗住院患者社区获得性肺炎的比较。
背景:在亚洲,估计每年有100万人死于社区获得性肺炎(CAP)。尽管老年人的死亡率很高,但大量CAP患者得到了治疗并存活下来,预期寿命达到了最佳水平。亚洲已经对成人CAP治疗方法进行了一些研究。此外,这些研究与欧洲数据之间也存在差异。我们的目的是研究口服左氧氟沙星(TAVANEX) 750 mg,每日1次,连续5天与口服头孢曲松1gr BD加口服阿奇霉素(250 mg,每日1次)7 - 10天(标准方案)在CAP治疗中的疗效。材料与方法:我们于2016年12月至2017年6月在阿尔博尔斯市Qaem医院对150例CAP患者进行了前瞻性随机试验。一组CAP患者随机分为两个治疗组。一组口服左氧氟沙星(TAVANEX), 750 mg,每日1次,连用5天;另一组口服头孢曲松1gr BD +口服阿奇霉素(250 mg,每日1次),连用7 - 10天(标准方案)。比较两组患者指定药物的疗效和副作用。P≤0.05为有统计学意义的概率水平。结果:两组治疗后体温(P值=0.09)、白细胞计数(P值=0.15)、呼吸音(P值=0.18)、入院时间(P值=0.15)差异均无统计学意义。在两组研究中均未见住院期间住院死亡率、临床恶化和抗生素用量增加的报告。标准方案组仅有2例(2.7%)患者出现皮疹,而左氧氟沙星组1例(1.3%)患者出现皮疹,2例(2.7%)患者出现胃肠道问题,3例(4%)患者出现中枢神经系统并发症。两组胸片均以网状结节型为多见。虽然标准方案组(n=27, 36%)比左氧氟沙星组(n=22, 29.3%)出现更多的实变,但左氧氟沙星组出现更多的磨玻璃型。结论:对于需要住院治疗的CAP患者,口服左氧氟沙星单药治疗与头孢曲松加阿奇霉素联合治疗同样有效。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Recent patents on anti-infective drug discovery
Recent patents on anti-infective drug discovery Medicine-Pharmacology (medical)
CiteScore
2.40
自引率
0.00%
发文量
1
期刊介绍: Recent Patents on Anti-Infective Drug Discovery publishes review articles on recent patents in the field of anti-infective drug discovery e.g. novel bioactive compounds, analogs & targets. A selection of important and recent patents on anti-infective drug discovery is also included in the journal. The journal is essential reading for all researchers involved in anti-infective drug design and discovery.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信